TESTOSTERONE ENANTHATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for testosterone enanthate and what is the scope of freedom to operate?
Testosterone enanthate
is the generic ingredient in three branded drugs marketed by Endo Pharms, Eugia Pharma, Hikma Farmaceutica, Nexus, Rising, Watson Labs, Watson Pharms Inc, and Antares Pharma Inc, and is included in nine NDAs. There are twenty-three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Testosterone enanthate has ninety-seven patent family members in fourteen countries.
There are eight drug master file entries for testosterone enanthate. Three suppliers are listed for this compound.
Summary for TESTOSTERONE ENANTHATE
International Patents: | 97 |
US Patents: | 23 |
Tradenames: | 3 |
Applicants: | 8 |
NDAs: | 9 |
Drug Master File Entries: | 8 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 55 |
Clinical Trials: | 39 |
Patent Applications: | 4,145 |
Drug Prices: | Drug price trends for TESTOSTERONE ENANTHATE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TESTOSTERONE ENANTHATE |
What excipients (inactive ingredients) are in TESTOSTERONE ENANTHATE? | TESTOSTERONE ENANTHATE excipients list |
DailyMed Link: | TESTOSTERONE ENANTHATE at DailyMed |
Recent Clinical Trials for TESTOSTERONE ENANTHATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The University of Texas Medical Branch, Galveston | Phase 2/Phase 3 |
North Florida/South Georgia Veterans Health System | Phase 2 |
North Florida Foundation for Research and Education | Phase 2 |
Pharmacology for TESTOSTERONE ENANTHATE
Drug Class | Androgen |
Mechanism of Action | Androgen Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for TESTOSTERONE ENANTHATE
US Patents and Regulatory Information for TESTOSTERONE ENANTHATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-001 | Sep 28, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-003 | Sep 28, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-003 | Sep 28, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TESTOSTERONE ENANTHATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-003 | Sep 28, 2018 | ⤷ Subscribe | ⤷ Subscribe |
Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-003 | Sep 28, 2018 | ⤷ Subscribe | ⤷ Subscribe |
Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-002 | Sep 28, 2018 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TESTOSTERONE ENANTHATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2022058684 | ⤷ Subscribe | |
China | 104487114 | Needle assisted jet injection administration of testosterone compositions | ⤷ Subscribe |
European Patent Office | 3177346 | AMORTISSEUR DE CHOCS POUR SERINGUE, DESTINÉ À ÊTRE UTILISÉ DANS UN DISPOSITIF D'INJECTION (A SYRINGE SHOCK ABSORBER FOR USE IN AN INJECTION DEVICE) | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
TESTOSTERONE ENANTHATE Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.